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One of the biggest risk factors for the development of breast
cancer is age, and over 40% of all breast cancers diagnosed
are in women aged 65 years or older [1]. Despite this, there
are few standardised guidelines for the management of older
breast-cancer patients, primarily due to the lack of level-I evi-
dence and the lack of representation of older women in adju-
vant therapy trials. Thus clinicians are often required to make
treatment decisions for elderly patients in the face of uncer-
tainty. This often leads to undertreatment, or less frequently,
overtreatment of elderly patients, with resultant poorer
outcomes.
In order to address this issue, a task force created by the
International Society of Geriatric Oncology (SIOG) and the
European Society of Breast Cancer Specialists (EUSOMA) has
developed a set of evidence-based guidelines for the manage-
ment of breast cancer in elderly individuals [2]. It is important
to note that these guidelines are predominantly applicable
only to elderly patients who are fit, rather than those who
are less fit or frail, due to the scarcity of data relating to treat-
ment of this latter group. Key recommendations are summa-
rised as follows.
• For an older individual with breast cancer it is critical that
all management decisions take into account physiological
age, life expectancy, potential risks versus absolute bene-
fits, treatment tolerance, patient preference and potential
barriers to treatment.
• Elderly breast-cancer patient management should involve
collaboration between geriatricians and oncologists.
Elderly patients are at higher risk for competing comorbid-
ities, which may not be evident on oncological assess-
ment. Comprehensive evaluation of functional status
with a multidomain geriatric assessment (CGA) is ideal,
although this may not be possible in all patients. Alterna-tively, it is reasonable to perform a functional screening
assessment to identify which patients are at increased risk
for functional deficits on the extended CGA. In patients in
whom reversible functional deficits are detected, proactive
management of these can improve quality of life and sur-
vival. Similarly, identification of interval decrease in func-
tional status through the use of repeated geriatric
assessments allows appropriate intervention and poten-
tially improved outcomes.
2. Early breast cancer
• Surgical options for patients 70 years or older should be
equivalent to those of younger patients, with age itself
not an indication for less-than-standard surgical manage-
ment. In some older patients it might be reasonable to
omit either sentinel lymph-node biopsy or completion
axillary lymph-node dissection, though this is an area of
ongoing debate.
• All elderly patients undergoing breast-conserving surgery
should be offered whole breast irradiation as a means to
significantly reduce local relapse rates. Elderly patients
with high-risk tumour (T3–4 or at least four lymph nodes
involved) should be considered for post-mastectomy
radiotherapy.
• Treatment of estrogen-receptor (ER) positive breast cancer
with endocrine therapy alone is a suitable treatment strat-
egy only in an elderly individual who has a limited life
expectancy (less than 3 years), who is considered unfit
for surgery after optimisation of medical conditions, or
who refuses surgery. Geriatrician input to guide the man-
agement of comorbidities and to accurately assess life
expectancy is strongly recommended.
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in older as in younger patients and are recommended as
initial adjuvant hormone therapies. The choice between
tamoxifen or aromatase inhibitors should be made by bal-
ancing the slightly higher efficacy of aromatase inhibitors
with the increased vulnerability of elderly patient to their
toxicities. For patients who commence on tamoxifen, a
switch from tamoxifen to aromatase inhibitor after 2–
3 years should be considered on the basis of treatment tol-
erability. Similarly, for healthy elderly patients, extended
endocrine therapy with an aromatase inhibitor after
5 years of tamoxifen is reasonable. In elderly patients with
very low-risk tumours (pT1aN0) or severe comorbidities,
the risks and toxicities of endocrine therapy may outweigh
the benefits; in these circumstances it may be reasonable
to omit adjuvant endocrine therapy.
• Fit elderly patients gain as much benefit as younger
patients from adjuvant chemotherapy. Chemotherapy
decisions should be made based on potential benefits,
which are highest in node-positive, hormone-negative dis-
ease, compared with risks and toxicities. Four cycles of an
anthracycline-containing regimens are usually preferred
over cyclophosphamide methotrexate 5-fluorouracil
(CMF). Substitution of anthracycline with taxane is also a
reasonable option to reduce the risk of cardiac toxicity.
• Adjuvant trastuzumab in combination with chemotherapy
should be offered to all elderly patients with HER2-positive
breast cancer, without cardiac disease, and who are suit-
able for chemotherapy treatment. Use of single-agent
trastuzumab in patients not suitable for chemotherapy
might be an option, although limited outcome data are
available in support of this approach.
3. Metastatic breast cancer
• Chemotherapy is indicated for ER-negative, hormone-
refractory, or rapidly progressing disease.
• Single-agent chemotherapy is generally preferred,
although oral combination chemotherapy is also a reason-
able option in elderly patients. There is no good evidence
in support of routine dose or schedule modifications in
elderly patients. However, this may be appropriate in cer-
tain circumstances, based on the known toxicities and
pharmacology of the chemotherapy agents coupled with
comorbidities in the patient.
• All patients with human epidermal growth factor receptor
2 (HER2) positive disease should be offered HER2-targeted
therapy. In fit elderly patients, anti-HER2 therapy should
be given in combination with chemotherapy. Anti-HER2
therapy plus endocrine therapy is a reasonable treatment
option in patients with HER2-positive ER-positive disease
in whom chemotherapy is contraindicated. Similarly
patients with HER2-positive ER-negative disease who are
not suitable for chemotherapy may be candidates for trast-
uzumab monotherapy.
• While bevacizumab has demonstrated benefit in terms of
improved progression-free survival in both elderly andyounger patients alike, concerns regarding both toxicities
and cost efficacy make its place in elderly breast cancer
management uncertain.
Increased comorbidities and polypharmacy are both more
common in elderly patients. Additionally, physiological age-
ing can be associated with altered pharmacokinetics (drug
absorption, distribution, metabolism and excretion). Each of
these factors can affect the efficacy and toxicity of anti-can-
cer agents, making it critical that drug prescription in elderly
patients be done with care. Eliminating or reducing the risk of
drug interactions is best achievedwith a thoroughmedication
review before making any treatment decisions.
Poor compliance or non-compliance with oral anti-cancer
medications is not uncommon in older breast-cancer patients
[3–5] and can lead to reduced efficacy of therapy. It is impor-
tant to consider causes of non-compliance, which may often
include poor tolerability of treatment. Thus, close adverse-
event monitoring and addressing specific toxicity concerns
and side-effects are crucial to improve compliance, treatment
tolerability and efficacy.
Older breast-cancer patients often rely more strongly on
the recommendation of the cancer specialist regarding breast
cancer management decisions; however, it is important to
recognise that some older patients may wish to take a more
active role in decision-making. While older patients are as
likely to accept therapy as younger patients, they may be less
willing to risk deterioration in quality of life for a potential
improvement in survival [6]. For this reason, careful and clear
discussions regarding diagnosis, prognosis and treatment op-
tions, as well as expectations of treatment and potential tox-
icities, are essential.
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